The Melanoma Nursing Initiative – Home › Forums › Targeted therapy › Other › Variants to mutations; fusions and › Reply To: Variants to mutations; fusions and
June 3, 2018 at 6:06 am #4847
Expert NurseKathleen Madden
Great question, tough topic, we have a few patients who have had varient mutations and when they failed immunotherapies we have utilized either a braf or a mek inhibitor to try and slow or arrest their disease. The inhibition is not as robust as with a true BRAF V600 E, K or M variant but the pt may receive some term of benefit. Approval of inhibotors for variant mutations, can either go smoothly or a letter of medical necessity may be required with a peer reviewed journal article &/ or a peer to peer may also be necessary.